```html

Wegener’s Granulomatosis (Granulomatosis with Polyangiitis) – A Comprehensive Guide

Overview

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare, chronic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis). This inflammation can cause necrotizing granulomas—clusters of inflamed cells—that most often affect the upper respiratory tract, lungs, and kidneys, but may involve any organ system.

• Who it affects: Typically adults aged 40–65, but it can occur at any age, including children.
• Gender distribution: Slight male predominance (about 55 % men).
• Prevalence: Approximately 3 cases per 100,000 people in the United States and Europe combined.<sup>[1]</sup>
• Geography: Rates are similar across North America, Europe, and Australia; it is rare in Asia and Africa.

GPA is part of a group called anti‑neutrophil cytoplasmic antibody (ANCA)–associated vasculitides. Early diagnosis and treatment dramatically improve survival—without therapy, median survival is 5 years, but with modern regimens >80 % survive beyond 10 years.<sup>[2]</sup>

Symptoms

Symptoms reflect the organs involved and often appear in a “stepwise” fashion. Because GPA can mimic infections or other disorders, a high index of suspicion is essential.

Upper Respiratory Tract

• Chronic sinusitis – nasal congestion, facial pain, foul‑smelling discharge.
• Nasal or oral ulcerations – painful sores that may bleed.
• Ear problems – otitis media, hearing loss, or vertigo.
• Nasopharyngeal granulomas – visible as “saddle‑nose” deformity when cartilage collapses.

Lungs

• Cough (dry or productive)
• Shortness of breath
• Chest pain, especially pleuritic
• Hemoptysis (coughing up blood) – a red‑flag symptom.
• Multiple nodules or cavitary lesions visible on chest imaging.

Kidneys

• Hematuria (blood in urine) – often microscopic.
• Proteinuria (protein in urine).
• Rapidly progressive glomerulonephritis leading to decreased urine output and swelling.

Other Organ Systems

• Skin: Palpable purpura, livedo reticularis, or necrotic ulcers.
• Eyes: Conjunctivitis, scleritis, or orbital inflammation causing pain and vision changes.
• Peripheral nerves: Mononeuritis multiplex – sudden loss of sensation or weakness in isolated nerve distributions.
• Musculoskeletal: Arthralgias, myalgias, or migratory arthritis.
• Gastrointestinal: Abdominal pain, melena, or intestinal perforation (rare).

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic predisposition, environmental exposure, and dysregulated immune responses.

Immunologic Mechanism

• Most patients have ANCA antibodies directed against proteinase‑3 (PR3‑ANCA). These antibodies activate neutrophils, causing them to adhere to vessel walls and release enzymes that damage tissue.
• In a minority, myeloperoxidase‑ANCA (MPO‑ANCA) is present, often with a slightly different clinical pattern.

Genetic Factors

• HLA‑DPB1*04 and HLA‑DPA1*02 alleles are associated with increased susceptibility.<sup>[3]</sup>
• Family history is uncommon, but first‑degree relatives have a modestly higher risk.

Environmental Triggers

• Silica dust exposure (e.g., mining, construction) has been linked to higher incidence.<sup>[4]</sup>
• Chronic nasal carriage of Staphylococcus aureus; some studies suggest eradication reduces relapse rates.
• Potential drug‑induced cases (e.g., propylthiouracil, cocaine adulterated with levamisole).

Who Is at Higher Risk?

• Adults 40–65 years old.
• Smokers and individuals with occupational silica exposure.
• People with a prior history of other autoimmune diseases (e.g., rheumatoid arthritis).

Diagnosis

Because symptoms overlap with infections, malignancies, and other vasculitides, a systematic approach is required.

Clinical Evaluation

• Detailed history focusing on nasal, pulmonary, and renal symptoms.
• Comprehensive physical exam (ENT, pulmonary auscultation, skin, neurologic assessment).

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in ~70–80 % of generalized GPA; MPO‑ANCA (p‑ANCA) in a smaller subset.
• Complete blood count (CBC) – anemia of chronic disease, leukocytosis.
• Renal panel – serum creatinine, BUN, electrolytes.
• Urinalysis – hematuria, proteinuria; microscopy for red cell casts.
• Inflammatory markers – ESR, CRP (usually elevated).

Imaging Studies

• Chest X‑ray or CT scan – reveals nodules, cavitations, or infiltrates.
• Sinus CT – assesses mucosal thickening, bone destruction.
• Renal ultrasound – helps evaluate kidney size, but biopsy is definitive.

Biopsy—The Gold Standard

Histologic confirmation of necrotizing granulomatous inflammation with vasculitis is required for a definitive diagnosis.

• Upper airway (nasal or sinus) biopsy – often yields diagnostic tissue with lower risk.
• Lung or kidney biopsy – considered when airway tissue is nondiagnostic.

Classification Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria assign points for ANCA status, organ involvement, and biopsy findings. A score ≥5 classifies the patient as having GPA.<sup>[5]</sup>

Treatment Options

Therapy aims to induce remission quickly, then maintain it with less toxic medication.

Induction Therapy (Rapid disease control)

• High‑dose glucocorticoids – intravenous methylprednisolone 500‑1000 mg daily for 3 days, then oral prednisone 1 mg/kg tapered over 6 months.
• Rituximab – anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4) is preferred for many patients, especially those with renal involvement or contraindications to cyclophosphamide.<sup>[6]</sup>
• or Cyclophosphamide – oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks). Requires monitoring for bladder toxicity and secondary malignancy.
• Adjunctive plasmapheresis – considered for severe pulmonary hemorrhage or rapidly progressive glomerulonephritis (KDIGO 2021 guidelines).

Maintenance Therapy (Prevent relapse)

• Azathioprine 2 mg/kg/day.
• or Mycophenolate mofetil 1‑1.5 g twice daily.
• Low‑dose rituximab (500 mg on day 0 and day 14, then every 6 months) is increasingly used based on the MAINRITSAN trial.
• Prednisone tapering to ≤5 mg/day by 12 months is standard.

Supportive and Symptom‑Targeted Care

• Prophylaxis against Pneumocystis jirovecii pneumonia (PJP) with trimethoprim‑sulfamethoxazole while on high‑dose steroids/ cyclophosphamide.
• Bone health: calcium, vitamin D, and bisphosphonates if glucocorticoid exposure >3 months.
• Vaccinations: influenza annually, pneumococcal (PCV15/20 + PPSV23), and COVID‑19 boosters – given before immunosuppression when possible.
• Smoking cessation and avoidance of silica exposure.

Living with Wegener’s Granulomatosis

Long‑term management focuses on monitoring disease activity, minimizing medication side effects, and maintaining quality of life.

Regular Follow‑Up

• Every 1‑3 months during induction; every 3‑6 months during remission.
• Labs each visit: CBC, CMP, ESR/CRP, ANCA titers (useful for trend, not sole decision‑maker).
• Urinalysis and renal function tests at each visit.
• Imaging (chest X‑ray or CT) if respiratory symptoms recur.

Self‑Monitoring Strategies

• Track sinus congestion, ear pain, cough, or hematuria in a symptom diary.
• Report new skin lesions, unexplained fatigue, or weight loss promptly.
• Use a medication calendar to avoid missed doses of immunosuppressants.

Lifestyle Recommendations

• Balanced diet rich in fruits, vegetables, lean protein, and omega‑3 fatty acids (anti‑inflammatory).
• Maintain a healthy weight; obesity may increase infection risk.
• Regular low‑impact exercise (walking, swimming) to preserve muscle mass and bone density.
• Stress‑reduction techniques (mindfulness, yoga) – stress can exacerbate autoimmune activity.

Psychosocial Support

• Consider counseling or support groups (e.g., Vasculitis Foundation). Chronic illness can lead to anxiety or depression.
• Ask your rheumatologist about patient‑education resources and financial assistance for costly biologics.

Prevention

Because the precise cause is unclear, prevention focuses on reducing known triggers and early detection.

• Avoid occupational silica exposure; use protective masks and adequate ventilation.
• Prompt treatment of chronic sinus infections; consider decolonization of S. aureus if recurrent.
• Do not use illicit drugs known to be adulterated with levamisole.
• Maintain routine health screenings to detect early renal or pulmonary changes.
• Adhere to vaccination schedules before initiating immunosuppressive therapy.

Complications

If left untreated or poorly controlled, GPA can lead to serious, potentially life‑threatening complications.

• Kidney failure – end‑stage renal disease requiring dialysis or transplantation.
• Severe pulmonary hemorrhage – can be fatal.
• Permanent respiratory impairment (fibrosis, bronchiectasis).
• Upper airway destruction – saddle‑nose deformity, chronic sinusitis, hearing loss.
• Peripheral nerve damage – persistent neuropathy.
• Increased risk of opportunistic infections due to immunosuppression.
• Secondary malignancies (particularly bladder cancer with cyclophosphamide).
• Medication toxicity – liver dysfunction, cytopenias, infertility.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Vasculitis Overview. 2022. Link.
2. Jennette JC, et al. “Granulomatosis with Polyangiitis.” New England Journal of Medicine. 2020;382:511‑521. Link.
3. Mauri C, et al. “Genetic susceptibility to ANCA-associated vasculitis.” Nature Genetics. 2020;52:447‑452. Link.
4. National Institute for Occupational Safety and Health. “Silica.” 2023. Link.
5. van Paassen P, et al. “2022 ACR/EULAR Classification Criteria for GPA.” Arthritis & Rheumatology. 2022;74(5):845‑854. Link.
6. Stone JH, et al. “Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.” NEJM. 2010;363:221‑232. Link.

**This guide is for educational purposes only and does not replace professional medical advice. If you suspect you have GPA or have concerns about your health, please consult a qualified healthcare provider.**

```